<DOC>
	<DOCNO>NCT00425308</DOCNO>
	<brief_summary>Efficacy safety 2 group treatment : everolimus association cyclosporine microemulsion steroid versus everolimus association Enteric-coated Mycophenolate Sodium ( EC-MPS ) steroid . The study population consist patient take part study CRAD001A2420 ( NCT00154297 ) end ( 12 month ) prematurely discontinue immunosuppressive regimen receive study ( everolimus + cyclosporine microemulsion + steroid ) .</brief_summary>
	<brief_title>Efficacy Safety Everolimus Combination With Cyclosporine Microemulsion Versus Everolimus Combination With Enteric-coated Mycophenolate Sodium ( EC-MPS ) , Adult Renal Transplant Patients Maintenance .</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion criterion : Patients participate complete study CRAD001A2420 Exclusion criterion : Premature study study treatment discontinuation CRAD001A2420 study . Acute rejection within 3 month prior inclusion Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Everolimus , calcineurine inhibitor , renal transplantation maintenance , chronic allograft nephropathy</keyword>
</DOC>